Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
LAG3 Antibody [2G8]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, IF, ICC, E |
|---|---|
| Primary Accession | P18627 |
| Other Accession | NP_002277 |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1,k |
| Clone Names | LAG3 |
| Calculated MW | Predicted: 55 kDa Observed: 60, 70, 80 kDa |
| Gene ID | 3902 |
|---|---|
| Alias Symbol | LAG3 |
| Other Names | LAG3 Antibody: lymphocyte activating 3, LAG-3, CD223 |
| Reconstitution & Storage | LAG-3 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Precautions | LAG3 Antibody [2G8] is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | LAG3 (HGNC:6476) |
|---|---|
| Synonyms | FDC |
| Function | Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:20421648, PubMed:7805750, PubMed:8647185). Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed:20421648, PubMed:7805750, PubMed:8647185). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:8647185). |
| Cellular Location | [Lymphocyte activation gene 3 protein]: Cell membrane; Single-pass type I membrane protein |
| Tissue Location | Primarily expressed in activated T-cells and a subset of natural killer (NK) cells. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The lymphocyte activation gene-3 (LAG3) is a member of the immunoglobulin superfamily and binds MHC class II with high affinity (1), negatively regulating T-cell function and homeostasis (2). It is expressed in B, T, and NK cells, monocytes, and dendritic cells (3), and acts to regulate T cell expansion (4). LAG3 is also an important immune checkpoint protein, with anti-LAG3 antibodies activating T effector cells and affecting regulatory T cell functions. Furthermore LAG3 appears to act in a synergistic fashion with PD-1/PD-L1, suggesting that a dual antibody approach may prove useful in cancer immunotherapy.
References
Huard B, Tournier M, Hercend T, et al. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol 1994; 24:3216–21.Triebel F. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 2003; 24:619–22.Workman CJ, Wang Y, El Kasmi KC, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol. 2009; 182:1885–91.Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 2003; 33:970–9.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
